11/06/2018
A Message From Your Bulletin Sponsor
Merck
10/30/18 - FDA Approves Keytruda in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC).
10/22/18 - Merck's Keytruda Significantly Improved Overall Survival Compared to Standard of Care as Monotherapy and in Combination with Chemotherapy as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer
For More Recent Merck News Releases CLICK HERE